Form 4 for IONS IONIS PHARMACEUTICALS INC
Accepted 2026-01-06 00:00:00 ET · period of report 2026-01-02 · accession 0000874015-26-000026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-01-06 | 2026-01-02 | IONS | Swayze Eric | EVP Research | M - OptEx | $60.89 | +23.5K | 48.8K | +93% | +$1.43M |
| DM | 2026-01-06 | 2026-01-02 | IONS | Swayze Eric | EVP Research | S - Sale+OE | $79.12 | -23.5K | 30.5K | -44% | -$1.86M |
| D | 2026-01-06 | 2026-01-02 | IONS | Swayze Eric | EVP Research | A - Grant | $0.00 | +19.4K | 19.4K | New | $0 |
| DM | 2026-01-06 | 2026-01-02 | IONS | Swayze Eric | EVP Research | M - OptEx | $0.00 | -23.5K | 22.4K | -51% | $0 |
| DI | 2026-01-06 | 2026-01-02 | IONS | Swayze Eric | EVP Research | A - Grant | $0.00 | +150 | 150 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | M | A | 5,125 | $60.89 | 35,578 | D | — | — | |
| 2 | Common | Common Stock | 2026-01-02 | S | D | 5,125 | $78.57 | 30,453 | D | — | — | (F1) Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.155 to $78.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. |
| 3 | Common | Common Stock | 2026-01-02 | M | A | 18,338 | $60.89 | 48,791 | D | — | — | |
| 4 | Common | Common Stock | 2026-01-02 | S | D | 18,338 | $79.27 | 30,453 | D | — | — | (F1) Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.88 to $79.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-01-02 | A | A | 19,350 | $0.00 | 19,350 | D | $79.67 · 2027-01-02 to 2036-01-01 | 19,350 Common Stock | (F4) Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-01-02 | M | D | 18,338 | $0.00 | 4,065 | D | $60.89 · 2020-01-02 to 2027-01-01 | 18,338 Common Stock | |
| 7 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-01-02 | A | A | 150 | $0.00 | 150 | I | $79.67 · 2027-01-02 to 2036-01-01 | 150 Common Stock | (F5) Grant on 01/02/2026 to reporting person's son of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. |
| 8 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-01-02 | M | D | 5,125 | $0.00 | 22,403 | D by Son | $60.89 · 2021-01-02 to 2027-01-01 | 5,125 Common Stock |